PMID- 17310137
OWN - NLM
STAT- MEDLINE
DCOM- 20070516
LR  - 20220331
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 39
IP  - 7
DP  - 2007 Apr
TI  - Fludarabine-based disease-specific conditioning or conventional myeloablative 
      conditioning in hematopoietic stem cell transplantation for treatment of 
      non-malignant diseases.
PG  - 383-8
AB  - Fludarabine-based conditioning (FBC) was given to 24 patients and conventional 
      myeloablative conditioning (MC) to 33 patients, most children, before 
      hematopoietic stem cell transplantation (HSCT) for non-malignant diseases. The 
      donors were human leukocyte antigen (HLA)-A, -B, -DRbeta1-identical related (33%) 
      or unrelated (67%). In the FBC group, two grafts failed versus three in the MC 
      group; all were successfully regrafted. Fever was more common in the MC patients 
      (P=0.003). Bacteremia occurred in 25% of the FBC group and 50% in the MC group 
      (P=0.1). In the FBC group, platelet engraftment was faster and transfusions were 
      fewer (P<0.05). Mucositis and renal function were similar in the two groups. The 
      MC group had higher maximum bilirubin (P=0.03) and less often normal spirometry 
      (P=0.04) after HSCT. A 7-year-old girl in the MC group had permanent alopecia. No 
      patients had severe acute graft-versus-host disease (GVHD). Chronic GVHD was 
      rare. Complete donor CD3+ chimerism was more common in the MC group (P=0.01), but 
      CD33+ engraftment was better with FBS (P=0.03). Treatment-related mortality was 4 
      and 15%, and 5-year survival was 89 and 85% in the FBC and MC groups. Although 
      survival was similar, FBC is a promising alternative to MC in non-malignant 
      disorders.
FAU - Ringden, O
AU  - Ringden O
AD  - Division of Clinical Immunology, Karolinska Institutet, Karolinska University 
      Hospital, Huddinge, Stockholm, Sweden. Olle.Ringden@ki.se
FAU - Remberger, M
AU  - Remberger M
FAU - Svenberg, P
AU  - Svenberg P
FAU - Svahn, B-M
AU  - Svahn BM
FAU - Dahllof, G
AU  - Dahllof G
FAU - Gustafsson, B
AU  - Gustafsson B
FAU - Hassan, Z
AU  - Hassan Z
FAU - Omazic, B
AU  - Omazic B
FAU - Uzunel, M
AU  - Uzunel M
FAU - Aschan, J
AU  - Aschan J
FAU - Barkholt, L
AU  - Barkholt L
FAU - Winiarski, J
AU  - Winiarski J
FAU - Ljungman, P
AU  - Ljungman P
FAU - Mattsson, J
AU  - Mattsson J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070219
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antineoplastic Agents)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anemia, Aplastic/*therapy
MH  - Antineoplastic Agents/*pharmacology
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Graft vs Host Disease
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Hemoglobinopathies/*therapy
MH  - Humans
MH  - Immunologic Deficiency Syndromes/*therapy
MH  - Infant
MH  - Male
MH  - Middle Aged
MH  - *Transplantation Conditioning
MH  - Vidarabine/*analogs & derivatives/pharmacology
EDAT- 2007/02/21 09:00
MHDA- 2007/05/17 09:00
CRDT- 2007/02/21 09:00
PHST- 2007/02/21 09:00 [pubmed]
PHST- 2007/05/17 09:00 [medline]
PHST- 2007/02/21 09:00 [entrez]
AID - 1705602 [pii]
AID - 10.1038/sj.bmt.1705602 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2007 Apr;39(7):383-8. doi: 10.1038/sj.bmt.1705602. Epub 
      2007 Feb 19.